In this episode of Just Bold Enough, Teymour and Felicia discuss an innovative biotech company, Syntis Bio, and how it will disrupt obesity treatment. Syntis has developed a gastric bypass-in-a-pill that blocks the absorption of glucose in the small intestine. This simple, yet clever solution could revolutionize the treatment of obesity and have a significant impact on the pharmaceutical industry by improving the delivery of other drugs. The team is led by experienced CEO, Rahul Dhanda, who is now leading the company into human clinical trials. The company also prioritizes health equity by aiming to disrupt the high cost of obesity treatments such as Ozempic and make it more accessible to those who need it. Story Notes: <ul><li> Addressing the Obesity Challenge</li><li>Navigating the Regulatory Landscape</li><li>The Potential Impact on the Pharmaceutical Industry</li></ul>To learn more, visit: <a href='https://boldcapitalpartners.com/'>https://boldcapitalpartners.com/</a>

Figure AI

Welcome to Just BOLD Enough, where we explore BOLD Capital Partner’s mission to invest in healthcare and technology companies that disrupt industries and uplift humanity. We’ll share expert insights and have engaging discussions on impact, investment philosophy, and our perspective on the very issues shaping our world. Get ready to embrace innovation with purpose – this is Just BOLD Enough.To learn more, visit:https://boldcapitalpartners.com/